126 related articles for article (PubMed ID: 22567936)
1. [New effects of telmisartan, an angiotensin 2 receptor blocker, in the treatment of arterial hypertension with metabolic disorders].
Demin AA; Shuliat'eva OIu
Klin Med (Mosk); 2012; 90(1):32-4. PubMed ID: 22567936
[TBL] [Abstract][Full Text] [Related]
2. Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril.
Smith DH
Clin Ther; 2002 Oct; 24(10):1484-501. PubMed ID: 12462282
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of telmisartan compared to enalapril in patients with severe hypertension.
Neutel JM; Smith DH; Reilly PA
Int J Clin Pract; 1999; 53(3):175-8. PubMed ID: 10665127
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
Barnett AH; Bain SC; Bouter P; Karlberg B; Madsbad S; Jervell J; Mustonen J;
N Engl J Med; 2004 Nov; 351(19):1952-61. PubMed ID: 15516696
[TBL] [Abstract][Full Text] [Related]
5. Dose response and safety of telmisartan in patients with mild to moderate hypertension.
Smith DH; Matzek KM; Kempthorne-Rawson J
J Clin Pharmacol; 2000 Dec; 40(12 Pt 1):1380-90. PubMed ID: 11185637
[TBL] [Abstract][Full Text] [Related]
6. Telmisartan.
McClellan KJ; Markham A
Drugs; 1998 Dec; 56(6):1039-44; discussion 1045-6. PubMed ID: 9878991
[TBL] [Abstract][Full Text] [Related]
7. ABPM comparison of the anti-hypertensive profiles of telmisartan and enalapril in patients with mild-to-moderate essential hypertension.
Amerena J; Pappas S; Ouellet JP; Williams L; O'Shaughnessy D
J Int Med Res; 2002; 30(6):543-52. PubMed ID: 12526280
[TBL] [Abstract][Full Text] [Related]
8. Changes in urinary albumin excretion, inflammatory and oxidative stress markers in ADPKD patients with hypertension.
Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Yamada S; Ueda Y; Koide H
Am J Med Sci; 2012 Jan; 343(1):46-51. PubMed ID: 21760473
[TBL] [Abstract][Full Text] [Related]
9. Antihypertensive effects of candesartan cilexetil, enalapril and placebo.
Franke H
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S61-2. PubMed ID: 9331010
[No Abstract] [Full Text] [Related]
10. Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension.
Zanchetti A; Omboni S; Di Biagio C
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S57-9. PubMed ID: 9331009
[No Abstract] [Full Text] [Related]
11. Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension--a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design.
Friedrich MG; Dahlöf B; Sechtem U; Unger T; Knecht M; Dietz R;
J Renin Angiotensin Aldosterone Syst; 2003 Dec; 4(4):234-43. PubMed ID: 14689371
[TBL] [Abstract][Full Text] [Related]
12. [The clinical and hemodynamic efficacy of telmisartan and enalapril in the treatment of arterial hypertension in patients with type 2 diabetes mellitus].
Tatarchenko IP; Pozdniakova NV; Mordovina AG; Morozova OI; Zaĭtseva AV
Ter Arkh; 2009; 81(12):11-5. PubMed ID: 20481040
[TBL] [Abstract][Full Text] [Related]
13. Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study.
Barnett AH
Acta Diabetol; 2005 Apr; 42 Suppl 1():S42-9. PubMed ID: 15868119
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate-renal failure patients with mild-to-moderate hypertension.
Hannedouche T; Chanard J; Baumelou B;
J Renin Angiotensin Aldosterone Syst; 2001 Dec; 2(4):246-54. PubMed ID: 11881131
[TBL] [Abstract][Full Text] [Related]
15. [Detail study of angiotensin-receptor blockade versus ACE-inhibition in type 2 diabetes with nephropathy].
Nitschmann S; Girndt M; Köhler H
Internist (Berl); 2005 Aug; 46(8):923-4, 926. PubMed ID: 15990988
[No Abstract] [Full Text] [Related]
16. [Arterial hypertension and type 2 diabetes mellitus: clinical evaluation of hemodynamic characteristics, possibility of correction].
Tatarchenko IP; Pozdniakova NV; Mordovina AG; Sekerko SA; Morozova OI
Klin Med (Mosk); 2009; 87(10):20-4. PubMed ID: 20017345
[TBL] [Abstract][Full Text] [Related]
17. Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?
Serebruany VL; Atar D; Hanley DF
Cerebrovasc Dis; 2008; 26(5):563-4. PubMed ID: 18936537
[No Abstract] [Full Text] [Related]
18. A comparison study of the echocardiographic changes in hypertensive patients treated with telmisartan vs. enalapril.
Hadi NR; Abdulzahra MS; Al-Huseini LM; Al-Aubaidy HA
Int J Cardiol; 2017 Mar; 230():269-274. PubMed ID: 28041700
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
[TBL] [Abstract][Full Text] [Related]
20. Impact of hypertension and antihypertensive treatment on organ damage.
Zanchetti A
Am J Cardiol; 1999 Jul; 84(2A):18K-24K. PubMed ID: 10437740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
